A French Protocol for the Treatment of Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE3

Total Enrollment

2044 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-09-19

Study Completion Date

2027-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A still major question in the field of acute lymphoblastic leukemia (ALL) in children - an extremely heterogeneous disease though curable in 80-90% of children and 70-80% of the adolescents - is the optimal use of L-asparaginase (ASNase). It is known that administering ASNase results in the depletion of asparagine circulating in the blood, which starves the leukemic cells and results in their death. But indeed the use of ASNase varies between protocols considering the different brands, the dose and the administration modalities. Oncaspar (PEGylated E. coli asparaginase, pegaspargase) was thus developed with the goal of reducing the immunogenicity of the native ASNase.

This is a French prospective multicentric cohort study of children and adolescents with ALL, stratified on (i) the type of ALL ( B vs T) and (ii) the anticipated risk (stratified in 3 groups for childhood B-cell precursor (BCP)-ALL and 2 groups for T-cell ALL).

It aims to answer to two different issues:

1. Randomized question: what is the best way to administer pegaspargase? A cohort of children and adolescents with standard or medium risk ALL will be randomized to receive during induction either one infusion of ONCASPAR® 2500 IU/m2 at D12 or two infusions of ONCASPAR® at 1250 IU/m2 each at D12 and D26. Patients will then receive 2500 IU/m2 or 1250 IU/m2 per dose during consolidation and delayed intensification according to the initial arm of randomization.
2. Non randomized question: In the High/Very High Risk groups, a non randomized intensification of the scheme of asparaginase administration is proposed during induction therapy: 2 infusions of 2500 IU/m2/day (D12 and D26) will be administered. All patients will receive 2500 IU/m2 per dose during consolidation and delayed intensifications.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Poly(Ethylene Glycol)(PEG)-Asparaginase During Two Treatment Courses

NCT00192673

Acute Lymphoblastic Leukemia

UNKNOWN PHASE4

Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration

NCT07221656

Childhood Acute Lymphoblastic Leukemia Childhood Lymphoblastic Lymphoma

NOT_YET_RECRUITING

Efficacy and Safety of Recombinant Asparaginase in Infants With Previously Untreated Acute Lymphoid Leukemia (ALL)

NCT00983138

Acute Lymphoid Leukemia

COMPLETED PHASE2

Exploring the Effect of Calaspargase Pegol on the Coagulation System in Pediatric Acute Lymphoblastic Leukemia (ALL) Patients: Pilot Study

NCT07071051

Childhood Acute Lymphoblastic Leukemia Childhood Lymphoblastic Lymphoma

RECRUITING

Study of Sirolimus With PEG-Asparaginase in Acute Lymphoblastic Leukemia (ALL)

NCT00957320

Acute Lymphoblastic Leukemia

WITHDRAWN PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Lymphoblastic Leukemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm 1

pegaspargase 2500 IU/m2 x 1: infusion of a conventional dose of pegaspargase during induction therapy: 2500 IU/m2x1

Group Type ACTIVE_COMPARATOR

pegaspargase 2500 IU/m2 x 1

Intervention Type DRUG

only for ALL of standard risk and medium risk

Arm 2

pegaspargase 1250 IU/m2 x 2: fractionation of the 2500 IU/m2 pegaspargase dose in two infusions of 1250 IU/m2 each during delayed intensification

Group Type EXPERIMENTAL

pegaspargase 1250 IU/m2 x 2

Intervention Type DRUG

only for ALL of standard risk and medium risk

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

pegaspargase 1250 IU/m2 x 2

only for ALL of standard risk and medium risk

Intervention Type DRUG

pegaspargase 2500 IU/m2 x 1

only for ALL of standard risk and medium risk

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ONCASPAR 1250 IU/m2 x 2 ONCASPAR 2500 IU/m2 x 1

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Children and adolescents Age \> 12 months but \< 18 yearsB-lineage or T- lineage ALL
* Written informed consent obtained before day 8 of treatment

* L3 (Burkitt's leukemia) (LMB type protocols)
* Mixed Phenotype Acute Leukemia (WHO criteria).
* Infant ALL (age ≤ 365 days (Interfant 06 protocol)
* Secondary leukemia
* Patients previously treated with chemotherapy (steroid exposed patients can be included and stratified according to Section 3.5) Known allergy to pegylated products
* Pregnancy. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant must have a negative serum pregnancy before inclusion and a reliable contraception except oral contraceptives. The contraception should be maintained throughout the study and for 3 months after treatment discontinuation.
* Known HIV positivity
* CNS thrombosis during Prophase